NEUROLIXIS
Neurolixis is a clinical-stage specialty pharmaceutical company focused on developing medicines targeting unmet disorders of the nervous system. The Company has two therapeutic candidates in clinical development: NLX-112, a potential symptomatic treatment for Parkinson's disease (PD) dyskinesia, is ready for Phase 2 clinical trials.
NEUROLIXIS
Industry:
Biopharma Biotechnology Health Care
Founded:
2011-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.neurolixis.com
Total Employee:
1+
Status:
Active
Contact:
9492144017
Total Funding:
15 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Font Awesome Domain Not Resolving Apache Google Apps For Business
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.neurolixis.com Semrush global rank: 4.73 M Semrush visits lastest month: 2 K
- Host name: node52-eu.n0c.com
- IP address: 185.221.182.142
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Neurolixis"
Home Page statement - Neurolixis
Neurolixis is an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system disorders including Parkinson's disease, rare autism spectrum …See details»
Company - Neurolixis
Neurolixis Inc. is an early-stage biopharmaceutical company developing novel treatments for disorders of the central nervous system. Neurolixis is advancing its drug discovery and …See details»
Neurolixis - Wikipedia
Neurolixis is a biopharmaceutical company focused on novel drugs for the treatment of human central nervous system diseases. Neurolixis Inc. was founded in 2011 by Mark A. Varney, PhD, and Adrian Newman-Tancredi, PhD, DSc.. The company's therapeutic focus is on CNS disorders including Parkinson's disease, neurological orphan disorders, depre…See details»
Neurolixis - Crunchbase Company Profile & Funding
Neurolixis is a clinical-stage specialty pharmaceutical company focused on developing medicines targeting unmet disorders of the nervous system. The Company has two therapeutic …See details»
Neurolixis Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Neurolixis. Use the PitchBook Platform to explore the full profile.See details»
Neurolixis - LinkedIn
Neurolixis Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including movement disorders,...See details»
Neurolixis Company Profile - Office Locations, Competitors, …
Neurolixis is an biopharmaceutical company. It focuses on the discovery and development of novel drugs for the treatment of human central nervous system disorders including Parkinson's …See details»
Neurolixis - VentureRadar
Neurolixis is an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system disorders …See details»
Early Trial Results Give Hope for a New Potential Dyskinesia …
Mar 20, 2023 · Neurolixis is developing a platform of drug candidates based on the concept of serotonin 5-HT1A receptor ‘biased agonism’ which enables drugs to more precisely target …See details»
Neurolixis - Contacts, Employees, Board Members, Advisors
Neurolixis has 2 current employee profiles, including CEO Mark Varney. Neurolixis is a biopharmaceutical company that develops drugs for the treatment of central nervous system …See details»
Team - Neurolixis
May 25, 2011 · At Neurolixis we believe that a key to success is to build a tightly-knit team of creative individuals with demonstrated track records of achievement in fundamental research, …See details»
Investing in a new treatment for dyskinesia | Parkinson's UK
Jan 24, 2018 · Parkinson's UK is partnering with US company Neurolixis to accelerate the development of a promising new drug that could prevent dyskinesia, one of the most …See details»
RSRT Awards $530,000 to Neurolixis for Clinical Development of …
Jun 24, 2015 · RSRT recently awarded $530,000 to Neurolixis, a small biotech firm in southern California that is developing the drug, NLX-101, to treat breathing abnormalities in people …See details»
Home Page statement - Neurolixis
Development of innovative molecules for the treatment of central nervous system diseasesSee details»
European Commission Grants NLX-112 Orphan Medicinal Product …
Oct 6, 2024 · Following a recent positive recommendation from the Committee for Orphan Medicinal Products, the European Commission has granted NLX-112 (Neurolixis), a highly …See details»
Management - Neurolixis
May 25, 2011 · Dr. Kleven has wide experience in small and mid-sized pharma companies as a pharmacologist and manager of FDA, NIH and DOD-compliant dossiers. He was previously …See details»
Neurolixis - Overview, News & Similar companies | ZoomInfo.com
Aug 22, 2023 · Neurolixis contact info: Phone number: (949) 214-4017 Website: www.neurolixis.com What does Neurolixis do? Neurolixis, located in Dana Point, California, is …See details»
Fragile X Treatment Target Emerges from Neurolixis & FRAXA ...
Jun 24, 2024 · Neurolixis, a FRAXA pharma partner, has announced a new Fragile X development program. The company has filed patents for treatment of Fragile X syndrome …See details»
Pipeline - Neurolixis
Neurolixis is developing a platform of early-stage drug candidates targeting serious CNS diseases with unmet medical needs and sizeable market opportunity. Compounds are based on the …See details»
News - Neurolixis
Neurolixis, Inc. today announced the positive results of its Phase 2A clinical trial with NLX-112 (befiradol), for treatment of levodopa-induced dyskinesias (LID) in Parkinson’s disease (PD).See details»